Feed NONOF
NO

Novo Nordisk A/S

NONOF · OTC

$40.02 -6.10% (-$2.60)
1M -9.03%
Market Cap 1.16T kr
P/E Ratio 9.95x
Div. Yield 4.50%
ROE 59.09%

Bulios Fair Price

$51.37

28.4% upside

Current Price

$40.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NONOF is currently undervalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
75 /100
Cheap
P/E 9.95x
P/FCF 15.22x
EV/EBITDA 7.01x
Growth
78 /100
Growing
EPS growth 23.43%
Book val. growth 32.36%
Rev. growth 20.34%
Profitability
100 /100
Strong
Gross margin 80.69%
FCF margin 23.12%
Net margin 35.35%
Quality
92 /100
Excellent
ROIC 29.73%
Asset turnover 0.55x
ROE 59.09%
Debt
61 /100
Moderate
Debt/Equity 0.63x
Net debt/EBITDA 0.53x
Current ratio 0.87x
Stability
48 /100
Moderate
Beta 0.35x
Profitable years 6
Rev. volatility 13.05%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NONOF
Online

About the company

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark, primarily known for its innovative products and treatments for diabetes. Founded in 1923, the company has grown to become a leader in insulin products as well as medications for obesity and other chronic diseases, such as hemophilia and growth disorders. Novo Nordisk operates globally, distributing its products in over 170 countries worldwide.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Maziar Mike Doustdar

Employees

68,794

Headquarters

Bagsvaerd

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.